Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.
Innovative companies whose purpose is to design and develop new ways to introduce drugs to the body. These new methods may consist of time-released capsules, differing injection techniques, or enabling certain drugs to be taken orally that may not have been to be taken so before. Their revenue is obtained from selling their technology to pharmaceutical companies or licensing it to manufacturers of prescription drugs.
|
| Totals |
Company |
Industry |
| Sales: |
$2,947.1 Mil |
$108,309.8 Mil |
| Market Cap: |
$862.4 Mil |
$395,990.5 Mil |
| Analysts Recommendation: |
Hold |
Buy |
|
|
| Averages |
Company |
Industry |
 |
| Growth |
| Historic Revenue: |
(15.0%) |
55.1% |
| Estimated Revenue: |
(2.6%) |
(17.5%) |
| Historic Earnings: |
(24.7%) |
19.2% |
| Estimated Earnings: |
(8.3%) |
(7.1%) |
| Stock Price (1 Year): |
(59.3%) |
44.5% |
| Cash per Share: |
10.8% |
447.5% |
| Dividend: |
N/A |
N/A |
| Price |
| Trailing PE: |
N/A |
N/A |
| Forward PE: |
1.6 |
20.2 |
| Price-to-Sales: |
.3 |
N/A |
| Price-to-Book: |
(1.7) |
7.8 |
| Dividend Yield: |
N/A |
N/A |
| Market Cap: |
$862.4 Mil |
$30,460.8 Mil |
| Operations |
| Net Margin: |
21.4% |
(24.4%) |
| Gross Margin: |
44.6% |
77.6% |
| Return on Equity: |
N/A |
(.4) |
| Return on Assets: |
(.1) |
(.1) |
| Balance Sheet |
| Current Ratio: |
1.2 |
4.2 |
| Quick Ratio: |
1.0 |
4.0 |
| Cash Ratio: |
.7 |
3.3 |
| Debt-to-Equity: |
N/A |
1.1 |
| Interest Coverage: |
.1 |
6.4 |
| Technicals |
| Relative-Strength Index: |
13.6 |
N/A |
|
|
|
